Day One Biopharmaceuticals, Inc. (DAWN) Dividend History

Day One Biopharmaceuticals, Inc. (DAWN) is a clinical-stage biotechnology company focused on developing innovative therapies for rare and severe neurological disorders. The company leverages its proprietary gene therapy platform to address unmet medical needs, primarily targeting pediatric patients with neurodegenerative and neurogenetic conditions.

2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005
Phone: 650 484-0899
Website: https://www.dayonebio.com

Dividend History

Day One Biopharmaceuticals, Inc. currently does not pay dividends

Company News

Global Cancer Antibody Drug Conjugates Market Size Forecast 2030

The global cancer antibody drug conjugates (ADCs) market is expected to surpass $50 billion by 2030, driven by the approval of 16 ADC drugs and over 500 ADCs in clinical trials. The market has experienced substantial growth, reaching over $7 billion in the first half of 2024, with ADCs offering improved efficacy and lower toxicity compared to traditional cancer treatments.

GlobeNewswire Inc.
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

Zacks Investment Research

Featured Companies: ALXO ANVS CGEN
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024

GlobeNewswire Inc.
Day One Announces Sale of Priority Review Voucher for $108 Million

BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).

GlobeNewswire Inc.
Day One Reports First Quarter 2024 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 09:50:42 UTC